|
||||||
|
 | |
| |
| |
| |
| |
|
Fusion gene ID: 13157 |
FusionGeneSummary for FBXO31_USP10 |
 Fusion gene summary |
| Fusion gene information | Fusion gene name: FBXO31_USP10 | Fusion gene ID: 13157 | Hgene | Tgene | Gene symbol | FBXO31 | USP10 | Gene ID | 79791 | 84669 |
| Gene name | F-box protein 31 | ubiquitin specific peptidase 32 | |
| Synonyms | FBX14|FBXO14|Fbx31|MRT45|pp2386 | NY-REN-60|USP10 | |
| Cytomap | 16q24.2 | 17q23.1-q23.2 | |
| Type of gene | protein-coding | protein-coding | |
| Description | F-box only protein 31SCF ubiquitin ligase specificity factorputative breast cancer tumor-suppressor | ubiquitin carboxyl-terminal hydrolase 32deubiquitinating enzyme 32renal carcinoma antigen NY-REN-60ubiquitin specific protease 32ubiquitin thioesterase 32ubiquitin thiolesterase 32ubiquitin-specific-processing protease 32 | |
| Modification date | 20180523 | 20180523 | |
| UniProtAcc | Q5XUX0 | Q14694 | |
| Ensembl transtripts involved in fusion gene | ENST00000311635, ENST00000563956, | ENST00000219473, ENST00000570191, ENST00000562743, | |
| Fusion gene scores | * DoF score | 3 X 2 X 3=18 | 6 X 5 X 5=150 |
| # samples | 3 | 6 | |
| ** MAII score | log2(3/18*10)=0.736965594166206 effective Gene in Pan-Cancer Fusion Genes (eGinPCFGs). DoF>8 and MAII>0 | log2(6/150*10)=-1.32192809488736 possibly effective Gene in Pan-Cancer Fusion Genes (peGinPCFGs). DoF>8 and MAII<0 | |
| Context | PubMed: FBXO31 [Title/Abstract] AND USP10 [Title/Abstract] AND fusion [Title/Abstract] | ||
| Functional or gene categories assigned by FusionGDB annotation | Tumor suppressor gene involved fusion gene, retained protein feature but frameshift. DDR (DNA damage repair) gene involved fusion gene, in-frame but not retained their domain. | ||
| * DoF score (Degree of Frequency) = # partners X # break points X # cancer types ** MAII score (Major Active Isofusion Index) = log2(# samples/DoF score*10) |
| Gene ontology of each fusion partner gene with evidence of Inferred from Direct Assay (IDA) from Entrez |
| Partner | Gene | GO ID | GO term | PubMed ID |
| Hgene | FBXO31 | GO:0006974 | cellular response to DNA damage stimulus | 19412162 |
| Hgene | FBXO31 | GO:0031146 | SCF-dependent proteasomal ubiquitin-dependent protein catabolic process | 19412162 |
| Fusion gene information from three resources (ChiTars (NAR, 2018), tumorfusions (NAR, 2018), Gao et al. (Cell, 2018)) * All genome coordinats were lifted-over on hg19. * Click on the break point to see the gene structure around the break point region using the UCSC Genome Browser. |
| Data type | Source | Cancer type | Sample | Hgene | Hchr | Hbp | Hstrand | Tgene | Tchr | Tbp | Tstrand |
| TCGA | LD | PRAD | TCGA-EJ-7218-01B | FBXO31 | chr16 | 87417011 | - | USP10 | chr16 | 84797692 | + |
| * LD: Li Ding group's fusion gene list RV: Roel Verhaak group's fusion gene list ChiTaRs fusion database |
| Open reading frame (ORF) analsis of fusion genes based on Ensembl gene isoform structure. * Click on the break point to see the gene structure around the break point region using the UCSC Genome Browser. |
| ORF | Henst | Tenst | Hgene | Hchr | Hbp | Hstrand | Tgene | Tchr | Tbp | Tstrand |
| Frame-shit | ENST00000311635 | ENST00000219473 | FBXO31 | chr16 | 87417011 | - | USP10 | chr16 | 84797692 | + |
| Frame-shit | ENST00000311635 | ENST00000570191 | FBXO31 | chr16 | 87417011 | - | USP10 | chr16 | 84797692 | + |
| 5CDS-intron | ENST00000311635 | ENST00000562743 | FBXO31 | chr16 | 87417011 | - | USP10 | chr16 | 84797692 | + |
| 5UTR-3CDS | ENST00000563956 | ENST00000219473 | FBXO31 | chr16 | 87417011 | - | USP10 | chr16 | 84797692 | + |
| 5UTR-3CDS | ENST00000563956 | ENST00000570191 | FBXO31 | chr16 | 87417011 | - | USP10 | chr16 | 84797692 | + |
| 5UTR-intron | ENST00000563956 | ENST00000562743 | FBXO31 | chr16 | 87417011 | - | USP10 | chr16 | 84797692 | + |
Top |
FusionProtFeatures for FBXO31_USP10 |
| Main function of each fusion partner protein. (from UniProt) |
| Hgene | Tgene |
| FBXO31 | USP10 |
| Component of some SCF (SKP1-cullin-F-box) protein ligasecomplex that plays a central role in G1 arrest following DNAdamage. Specifically recognizes phosphorylated cyclin-D1 (CCND1),promoting its ubiquitination and degradation by the proteasome,resulting in G1 arrest. May act as a tumor suppressor.{ECO:0000269|PubMed:16357137, ECO:0000269|PubMed:19412162}. | Hydrolase that can remove conjugated ubiquitin fromtarget proteins such as p53/TP53, BECN1, SNX3 and CFTR. Acts as anessential regulator of p53/TP53 stability: in unstressed cells,specifically deubiquitinates p53/TP53 in the cytoplasm, leading tocounteract MDM2 action and stabilize p53/TP53. Following DNAdamage, translocates to the nucleus and deubiquitinates p53/TP53,leading to regulate the p53/TP53-dependent DNA damage response.Component of a regulatory loop that controls autophagy andp53/TP53 levels: mediates deubiquitination of BECN1, a keyregulator of autophagy, leading to stabilize the PIK3C3/VPS34-containing complexes. In turn, PIK3C3/VPS34-containing complexesregulate USP10 stability, suggesting the existence of a regulatorysystem by which PIK3C3/VPS34-containing complexes regulatep53/TP53 protein levels via USP10 and USP13. Does notdeubiquitinate MDM2. Deubiquitinates CFTR in early endosomes,enhancing its endocytic recycling. Involved in a TANK-dependentnegative feedback response to attenuate NF-kappaB activation viadeubiquitinating IKBKG or TRAF6 in response to interleukin-1-beta(IL1B) stimulation or upon DNA damage (PubMed:25861989).Deubiquitinates TBX21 leading to its stabilization(PubMed:24845384). {ECO:0000269|PubMed:11439350,ECO:0000269|PubMed:18632802, ECO:0000269|PubMed:19398555,ECO:0000269|PubMed:20096447, ECO:0000269|PubMed:21962518,ECO:0000269|PubMed:24845384, ECO:0000269|PubMed:25861989}. |
| Retention analysis result of each fusion partner protein across 39 protein features of UniProt such as six molecule processing features, 13 region features, four site features, six amino acid modification features, two natural variation features, five experimental info features, and 3 secondary structure features. Here, because of limited space for viewing, we only show the protein feature retention information belong to the 13 regional features. All retention annotation result can be downloaded at . * Minus value of BPloci means that the break pointn is located before the CDS. |
| - In-frame and retained protein feature among the 13 regional features. |
| Partner | Gene | Hbp | Tbp | ENST | Strand | BPexon | TotalExon | Protein feature loci | *BPloci | TotalLen | Protein feature | Protein feature note |
| - In-frame and not-retained protein feature among the 13 regional features. |
| Partner | Gene | Hbp | Tbp | ENST | Strand | BPexon | TotalExon | Protein feature loci | *BPloci | TotalLen | Protein feature | Protein feature note |
Top |
FusionGeneSequence for FBXO31_USP10 |
| For in-frame fusion transcripts, we provide the fusion transcript sequences and fusion amino acid sequences. (nt: nucleotides, aa: amino acids) |
| * Fusion amino acid sequences. |
| * Fusion transcript sequences (only coding sequence (CDS) region). |
| * Fusion transcript sequences (Full-length transcript). |
Top |
FusionGenePPI for FBXO31_USP10 |
| Go to ChiPPI (Chimeric Protein-Protein interactions) to see the chimeric PPI interaction in . |
| Protein-protein interactors with each fusion partner protein in wild-type (BIOGRID-3.4.160) |
| Hgene | Hgene's interactors | Tgene | Tgene's interactors |
| FBXO31 | CUL1, SKP1, RBX1, CCND1, COPS5, PARD6A, MAP2K6, CDT1, STX3, PDLIM1, MRPS27, EFR3A, EDRF1, MYH6, PRPS1, CEP170P1, QSER1, C18orf21, ZCCHC9, FAM58A, DNAJC19, GHR, MDM2, ZNF131, FOXM1, FAM98A, STYX, SNAI2, SNAI1 | USP10 | G3BP1, SNX3, SCNN1A, EIF4G1, EIF4G3, G3BP2, CELF1, GAR1, ULK1, TP53, MDM2, CFTR, UBC, AR, WAPAL, ZC3H18, USP15, UBE2S, TSKS, TRPM8, ZNF281, PABPC1, VCP, TARDBP, ANKRD28, PPP6R1, PPP6R3, HECW2, PTEN, ZC3H12A, IKBKG, PCNA, TBX21, USP10, SIRT6, KLHDC3, SF3B3, NTRK1, RAD51, NPM1, RPL10, NOP56, IBTK, PRKAA1, PRKAA2, YBX1, KMT2E, CDC5L, TBP, TANK, TRAF6, HIST2H2AC, MSH2, SNAI1, ANKRD44, ANKRD52, AARSD1, SMEK1, GFAP, PPP6R2, PPP4R2, CYLD, ZEB1, RNF168, RPS6 |
| - Retained PPIs in in-frame fusion. |
| Partner | Gene | Hbp | Tbp | ENST | Strand | BPexon | TotalExon | Protein feature loci | *BPloci | TotalLen | Still interaction with |
| - Lost PPIs in in-frame fusion. |
| Partner | Gene | Hbp | Tbp | ENST | Strand | BPexon | TotalExon | Protein feature loci | *BPloci | TotalLen | Interaction lost with |
| - Retained PPIs, but lost function due to frame-shift fusion. |
| Partner | Gene | Hbp | Tbp | ENST | Strand | BPexon | TotalExon | Protein feature loci | *BPloci | TotalLen | Interaction lost with |
Top |
RelatedDrugs for FBXO31_USP10 |
| Drugs targeting genes involved in this fusion gene. (DrugBank Version 5.1.0 2018-04-02) |
| Partner | Gene | UniProtAcc | DrugBank ID | Drug name | Drug activity | Drug type | Drug status |
Top |
RelatedDiseases for FBXO31_USP10 |
| Diseases associated with fusion partners. (DisGeNet 4.0) |
| Partner | Gene | Disease ID | Disease name | # pubmeds | Source |
Copyright 2018-Present -The University of Texas Health Science Center at Houston (UTHealth)
|